GDF15 level remained unchanged following treatment with liraglutide or lorcaserin in obesity patients, indicating that it does not directly participate in the metabolic feedback pathways activated by GLP1R agonists [93]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.